Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2013 16:01 ET | Source: Zogenix

Zogenix Reports First Quarter 2013 Financial Results

Provides Update on Zohydro ER Conference Call and Webcast Today, May 9, at 4:30 p.m. ET SUMAVEL® DosePro® (sumatriptan injection) First Quarter 2013 Highlights Net product...
May 03, 2013 07:30 ET | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
May 02, 2013 07:30 ET | Source: Zogenix

Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial

SAN DIEGO, May 2, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
March 27, 2013 08:00 ET | Source: Zogenix

Zogenix and Battelle Extend DosePro Co-Marketing Partnership

SAN DIEGO and COLUMBUS, Ohio, March 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
March 15, 2013 07:30 ET | Source: Zogenix

Zogenix Reports Fourth Quarter and Full Year 2012 Financial Results

SUMAVEL® DosePro® (sumatriptan injection) Highlights 2012 net product revenue of $35.9 million, up 18% over 2011 Fourth quarter net product revenue of $9.5 million, up 12% over...
March 07, 2013 07:30 ET | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2012 Financial Results

SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
February 26, 2013 20:05 ET | Source: Zogenix

Zogenix Provides Update on Zohydro(TM) ER Regulatory Review

SAN DIEGO, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
January 07, 2013 07:30 ET | Source: Zogenix

Zogenix Announces Preliminary Fourth Quarter 2012 Gross Product Sales

SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
January 03, 2013 07:30 ET | Source: Zogenix

Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
December 07, 2012 17:45 ET | Source: Zogenix

Zogenix Provides Update on FDA Advisory Committee Meeting for Zohydro(TM) ER for Management of Chronic Pain

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right